Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China

Table 4 Treatments and outcomes of hospitalized patients with coronavirus disease 2019, n (%)

	Total (n = 65)	Nonsevere (n = 49)	Severe (n = 16)	P value
Antiviral therapy
Oseltamivir	12 (18.5)	8 (16.3)	4 (25)	0.685
Arbidol	40 (61.5)	32 (65.3)	8 (50)	0.275
Ribavirin	3 (4.6)	3 (6.1)	0	0.569
Lopinavir/Ritonavir	35 (53.8)	22 (44.9)	13 (81.3)	0.011
Interferon	21 (32.3)	16 (32.7)	5 (31.3)	0.917
Chloroquine	1 (1.5)	0	1 (6.3)	0.246
Antibiotic therapy	36 (55.4)	21 (42.9)	15 (93.8)	< 0.001
Antifungal therapy	1 (1.5)	0	1 (6.3)	0.246
Glucocorticoid therapy	12 (18.5)	2 (4.1)	10 (62.5)	< 0.001
Immunoglobulin	3 (4.6)	0	3 (18.8)	0.013
Thymosin	11 (16.9)	4 (8.2)	7 (43.8)	0.004
Traditional Chinese medicine	51 (78.5)	38 (77.6)	13 (81.3)	1
Oxygen support	20 (30.8)	4 (8.2)	16 (100)	< 0.001
Nasal cannulas	20 (30.8)	4 (8.2)	16 (100)	< 0.001
HFNC	6 (9.2)	0	6 (37.5)	< 0.001
NIV	1 (1.5)	0	1 (6.3)	0.246
IMV	1 (1.5)	0	1 (6.3)	0.246
ECMO	1 (1.5)	0	1 (6.3)	0.246
Prone position	6 (9.2)	0	6 (37.5)	< 0.001

COVID-19: Coronavirus disease 2019; HFNC: High-flow nasal cannula; NIV: Noninvasive ventilation; IMV: Invasive mechanical ventilation; ECMO: Extracorporeal membrane oxygenation.